• OPEN AN ACCOUNT
Indian Indices
Sensex
81,537.70 -769.67
( -0.94%)
Global Indices
Nasdaq
49,128.98 -276.04
(-0.56%)
Dow Jones
6,938.97 4.62
(0.07%)
Hang Seng
53,831.56 142.67
(0.27%)
Nikkei 225
10,138.52 -11.53
(-0.11%)
Forex
USD-INR
91.58 0.09
(0.10%)
EUR-INR
107.27 0.14
(0.13%)
GBP-INR
123.20 0.33
(0.27%)
JPY-INR
0.58 0.00
(-0.17%)

EQUITY - MARKET SCREENER

Kilitch Drugs (India) Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
524500
INE729D01010
180.7312064
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KILITCH
17.28
548.98
EPS(TTM)
Face Value()
Div & Yield %
18.17
10
0
 

Havells India to acquire stake in solar SPV for captive consumption
Nov 26,2025
Havells India has approved acquiring a stake of 26% in Kundan Solar (Pali), a Special Purpose Vehicle (SPV), established for the business of developing, installing, operating, managing and maintaining solar power plant.

The purpose of this transaction is to strategically reduce dependence on fossil fuel and move towards green energy. Kundan Solar will set up a 15 MWac solar power plant and Havells plan to enter into a long-term Power Purchase Agreement (PPA) up to 25 years. Under the Electricity Laws, Havells is required to hold a minimum of 26% shareholding to qualify as a captive consumer.

The arrangement will result in savings in power cost at plant locations in Rajasthan with payback within ~12-18 months from date of commissioning of the project.